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IT has been reported previously from this laboratory (Woodruff and Symes,
1962) that the growth of an A-strain mouse mammary carcinoma transplanted to
isogenic hosts is retarded if the tumour-inoculated animals are given a sublethal
dose of whole body irradiation (400 r) followed by an intravenous injection of
spleen cells from a mouse of a different strain (CBA) immunized against the
tumour; a significant anti-tumour effect was however achieved only at the cost of
producing severe and often fatal graft-versus-host disease in the treated animals.
In the experiments cited, irradiationalone, and injection ofspleen cellswithout
prior irradiation, were ineffective. It seemed likely that in the combined treat-
ment the effect ofthe irradiation was to delay rejection ofthe transplanted spleen
cells, but there was no formal proof of this. It appeared desirable, therefore, to
make further observations with the same type of tumour but under conditions in
which immunological rejection of the transplanted spleen cells could be avoided
without recourse to irradiation or the use of immunosuppressive drugs. This
requirement can be met by maintaining the tumour in the F1 hybrid of two
homozygous strains, one being the strain of origin of the tumour and the other
(referred to later as the " foreign parent strain ") the strain used to provide the
spleen cells.
A system ofthis kind was used by Wigzell (1960), who showed that the growth
of various mouse lymphomas in F1 hybrids could be inhibited by injecting lym-
phoid cells from the foreign parent strain, provided that this injection was made
five days before inoculating the tumour or, when the lymphoid cells were obtained
from preimmunized donors, at the same time as the tumour inoculation. On the
other hand when the tested tumour was a sarcoma or a mammary carcinoma little
if any inhibition occurred and all the mice died with tumours.
The experiments now reported differ from those of Wigzell in that no foreign
strain cells were injected until 7 days after inoculation ofthe tumour, and tumour
cells rather than tumour-strain spleen andlymph node cells were used to immunize
the foreign-strain spleen cell donors.
MATERIALS AND METHODS
General plan of the experiment
Sixty adult (20-25 g.) female (CBA x A) F1 hybrid mice were each given on
Day 0 a subcutaneous injection of 20 million cells (of which approximately 20
per cent were non-viable as judged by the trypan blue test) prepared from a single
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first-generation tumour transplant in an A-strain female mouse which had itself
received an injection of 20 million cells from a spontaneous A-strain mammary
carcinoma (No. LXIX) 35 days previously. These mice were allocated at random
into three groups ofpredetermined size designated R0, RI and R3, containing 12,
16 and 32 animalsrespectively. SubsequentlythemembersofgroupRO were kept
as untreated controls; those ofgroup RI received a single intravenous injection of
100 million spleen cells from pre-immunized CBA donors on day 7; and those of
group R3 receivedthree suchinjections, the first onDay 7, the next on Day 14 and
the last on Day 21. The number of mice in each group was chosen to allow for
wastage due to accidental death at the time ofthe spleen cell injections and it was
hoped to end up with at least 12 animals in groups RO and RI, and 24 in R3; in
the event the numbers turned out to be 12, 16 and 25 respectively.
The CBA spleen cell donors were all immunized by 3 intraperitoneal injections
of 20 million tumour cells at weekly intervals and the spleens were harvested 1
week after the last injection. These donors are designated D7, D14 or D21
according to the day ofthe experiment (reckoned from Day 0) on which the spleen
cells were harvested and injected into the tumour-bearing hybrids. The tumours
used to immunize these donors were also first generation transplants from the same
original spontaneous mammary carcinoma No. LXIX. The schedule of im-
munization is shown in Fig. 1, from which it will be seen that the suspension
which was used to inject the hybrid tumour recipients (groups RO, RI and R3)
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FIG. 1.-General plan ofexperiment. RO, RI and R3 denote groups of (CBA x A) F1 hybrids
which were used as tumour recipients; D7, D14 and D21 denote CBA mice which were used
as spleen cell donors after being immunized against the A-strain tumour. The RO mice
were kept as controls and received no treatment. The RI mice received a single intravenous
injection of 100 million spleen cells on Day + 7 from D7 donors. The R3 mice received
three intravenous injections of 100 million spleen cells on Days + 7 (from D7 donors), + 14
(from D14 donors) and + 21 (from D21 donors) respectively.
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was also used to provide the last immunizing injection for the D7 CBA spleen cell
donors.
The tumour recipients were inspected and weighed twice weekly. Ifa tumour
was present measurements of its size were made with a caliper in its long axis and
in the direction perpendicular to this. The arithmetic mean of these measure-
ments for any given tumour is referred to as the mean tumour diameter, and the
arithmetic mean ofthe mean tumour diameters ofall the mice in a particular group
at a given time is referred to as the group mean diameter.
Preparation of cell suspen8ions
Spleen cell suspensions were prepared as described previously (Woodruff and
Symes, 1962). Tumour cell suspensions were prepared in a similar way after first
cutting up the tumour into small fragments with a pair ofknives and removing all
necrotic looking tissue. Total and non-viable cell counts were made in a haemo-
cytometer after diluting the suspension with 2 per cent acetic acid in water and
0O05 per cent trypan blue in Hanks' solution respectively.
RESULTS
In the control mice (group RO) thetumours grew progressively and, as shown in
Fig. 2, ifthe group mean diameter is plotted against time the points lie on or very
I
z
4
Id
,a
-o
0
CONTROLS. NO TREATMENT
---O 100 X 106 IMMUNISED SPLEEN CELLS
I. V. ON DAY 7
- -x 100 X 106 IMMUNISED SPLEEN CELLS
I. V. ON DAYS 7,14,21
TIME - DAYS
FIG. 2.-Group mean tumour diameter plotted against time for control and treated (CBA x A) F1
hybrids inoculated subcutaneously with 20 million A-strain mammary carcinoma cells.
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close to a straight line for the period from Day 8 to Day 35. Tumours also grew
progressively in all the mice whichreceived a single spleen cell injection (group RI),
but there was a sudden decrease in growth rate at Day 14 (i.e. 7 days after the
treatment) and two straight lines are required to fit the data. In the group (R3)
which received three spleen cell injections tumours appeared in all the mice but
subsequently regressed completely in two of them and have not since recurred;
in the remainder the tumours grew progressively but again there was a sudden
decrease in growth rate at Day 14, which was more marked than that observed in
group R2.
It was thought likely from the observations made during the preparatory
phase ofthe experiment (Day - 35 to Day 0), and from experience with other A-
strain mammarycarcinomas, thatmost ofthehybrid tumourrecipientswouldhave
palpable but small tumours by Day 7 when the first spleen cell injections were due
to be given. This turned out to be the case. In fact 53 ofthe 59 animals alive on
Day 7 hadpalpable tumours, butallofthese had ameandiameterofless than 5mm.
The statistical significance of the observed changes in growth rate may be
assessed from the data in Table I, which shows the increment in mean diameter
TABLE I.-Significance of Differences in Tumour Growth Rate in Treated and
Untreated Mice
Group
Controls (RO)
No. of
mice
in
group
. 11*
Single treatment (RI). 12*
Multiple treatment . 23t
(R3)
All treated mice. . 35*t
(RI + R3)
Increment in mean tumour diameter
from Day 14 to Day 28
-F- -
Group
mean
Individual values (mim.) (mm.)
12-5, 16-5, 9-5, 8-0, 15-5, 19-0 14-95
16-0, 15-5, 19-5, 16-5, 16-0
9-0, 20*0, 11*5, 6-5, 1850, 12-0, 11-58
17 5, 6-5, 11-5, 8-0,10-0, 8-5
10-5, 9-5, 8-0, 1-5, 14-5, 10-5,
8-0, 3 5,9 0, 8-5, 12-5, 12*5,
11-5,11-0,10-5,10-0,7.0,9 0,
9*5, 16-0, 6-0, 12-0, 9 0
t See above
* Excludes mice which died before Day 28.
t Excludes two mice whose tumours regressed completely
discussed separately.
Statistical comparison
with controls
Bailey's
Fisher's modified
t-test t-test
t =1-95 "t"=1-975
n =21- f=20- P <0-07 P <0-07
9*56 t =4*44 "t"=4-2
n =32 f =17
P <0.001 P<0.001
10-26 t =3*62 "t"=3 73
n =44 f =17
P<0-001 P<0-002
during treatment and which are
for the tumours in eachgroup ofanimals from Day 14 to Day 28. The group mean
increments have been calculated and compared by Fisher's t-test, and also by the
modified "f " test described by Bailey (1959), which makes it possible to assess the
significance of the difference between the means of two small samples without
assuming that they are drawn from populations having the same variance. It
will be seen that the decrease in growth rate for the mice which received a single
spleen cellinjection liesjust below the conventional level ofsignificance, but for the
mice whichreceived three injections, and for the treated mice as a whole, the fall is
highly significant. The complete regression oftwo tumours in the animals which
received three spleen cell injections isparticularly impressive because much smaller
doses of the mammary carcinoma used in these experiments, and of other similar
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tumours, have been uniformly successful in producing tumours in (CBA x A) F1
hybrids, and we have never observed complete regression of an established trans-
plant of any of these tumours in an untreated host.
TABLE II.-Period of Survival of Treated and Untreated Tumour-bearing Mice
Period ofsurvival (Days)
No. ofmice , --.
Group in group Individual values Mean for group
Controls (R0) . . 12 . 44, 32, 28, 32, 32, 50, 34, 27, 69, 42, 42,40 39.3
Single treatment (RI) 15 37, 20, 59, 32, 64, 39, 51, 20, 56, 20, 42, 29, 35, 40 7
56, 50
Multiple treatment (R3). 25 . 56, 84, 33, 44, 38, 120t, 29, 29, 31, 50, 44, 52-1*
120t, 47, 45, 50, 47, 71, 40, 62, 55, 40, 36, 44,
39,49
* The experiment was terminated on Day 120 and in calculating this mean a survival time of 120
days has therefore been assigned to the two surviving animals in the group whose tumours had
regressed.
t Denotes " alive at end of experiment."
The length of survival of the animals in each group is shown in Table II, and
the cumulative mortality in groups RO and R3 is shown in Fig. 3. If the figures
are rearranged to show the number of animals dying before Day 30, after Day 69
and in the 10-day periods in between, it will be seen that there is more than a hint
ofbimodality inthetreated groups. This suggests thatagraft-versus-hostreaction
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FIG. 3.-Chart showing the percentage of (CBA x A) F1 hybrid mice surviving at any given
time after being inoculated subcutaneously with 20 million A-strain mammary carcinoma
cells. The treated group (broken line) received intravenous injections of 100 million pre-
immunized spleen cells on Day 7, Day 14 and Day 21.
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may have played some part in determining the time ofdeath, but there were only 3
mice (all in group R1) in which this appeared to be the sole, or even the main,
factor. Because of the large variance it was not expected that the difference of
12-8 days in the mean survival times in groups R3 and RO would prove to be sig-
nificant, and a t-test has confirmed this surmise.
DISCUSSION
The results show that the growth of transplants of an A-strain mammary
carcinoma in (CBA x A) F1 hybrid hosts may, under the conditions of the
experiment, be inhibited by the injection of spleen cells from CBA donors im-
munized against the tumour. It is noteworthy that this inhibition occurred
despite the fact that no spleen cells were injected until 7 days after tumour cell
inoculation, by which time palpable tumours were present in 90 per cent of the
mice. It would seem to be ofinterest to study the effect ofvarying the time of a
single spleen cell injection in relation to the time ofinoculation ofthe tumour, and
experiments of this kind are in progress.
It appears that three successive injections of spleen cells at weekly intervals
have a greater inhibitory effect than a single injection. Further experiments
have been set up to try to determine the therapeutically optimal way of distri-
buting a constant total dose of such cells.
It is of interest that no change in tumour growth rate was observed until 7
days after the first injection of spleen cells, particularly in view of the fact that
these cells were obtained from immunized donors. Once again, however, further
experiments are required to elucidate the significance of this time-relationship.
Wigzell (1960), in the experiments cited earlier, showed that only slight tumour
inhibition occurred when F1 hybrids were given tumour (lymphoma) cells and
lymphoid cells from the same parent strain. Since in his system lymphoid cells
from either parent strain were about equally effective in producing graft-versus-
host disease when injected into the F1 hybrid he argued that the inhibition which
occurredwhenheusedlymphoid cellsfrom theforeignparent strainwasdue mainly
to a specific anti-tumour effect, though he considered that there was probably also
a small non-specific component, attributable at least in part to graft-versus-host
disease.
We have preferred to attack the same question in a different way, namely, by
studying the effect of A-strain spleen cells on tumours originating in, and trans-
planted in, mice of this strain, thus completely eliminating graft-versus-host
disease. Experiments of this kind are in progress and will be reported later.
Meanwhile, however, in view of the relative mildness of graft-versus-host disease
in our system, it seems very unlikely that this could account fully for the observed
tumour inhibition, though it may have contributed to some extent.
SUMMARY
Ithas been shown that the growth oftransplants ofanA-strainmousemammary
carcinoma in (CBA x A) F1 hybrid recipients may be inhibited by the intravenous
injection of spleen cells from CBA mice immunized against the tumour, starting 7
days after tumour inoculation. In only 3 out of60 mice could death be attributed
to graft-versus-host disease. It is suggested that the inhibition was due at least in
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part to a specific anti-tumour effect, and further experiments bearing on this point
are proposed.
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